refractory Langerhans cell histiocytosis (DBCOND0022006)

Identifiers

Synonyms

Refractory Langerhans Cell Histiocytosis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Clofarabine	A purine nucleoside used to treat relapsed or refractory acute lymphoblastic leukemia in patients 1 to 21 years old.	DNA polymerase alpha catalytic subunittarget Ribonucleoside-diphosphate reductase large subunittarget Deoxycytidine kinaseenzyme DNAtarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Ribonucleoside-diphosphate reductase subunit M2target Ribonucleoside-diphosphate reductase subunit M2 Btarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04284774	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Tipifarnib	treatment	2	active_not_recruiting
NCT05828069	A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis	Tovorafenib	treatment	2	recruiting
NCT03210714	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Erdafitinib	treatment	2	active_not_recruiting
NCT03213678	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	LY-3023414	treatment	2	active_not_recruiting
NCT03213704	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	Larotrectinib Sulfate ion	treatment	2	active_not_recruiting
NCT04320888	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Selpercatinib	treatment	2	active_not_recruiting
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Ensartinib Erdafitinib Hydrogen LY-3023414 Larotrectinib Menthol Olaparib Palbociclib Selpercatinib Selumetinib Sulfate ion Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-396	screening	2	recruiting
NCT03213652	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Ensartinib X-396	treatment	2	recruiting
NCT03526250	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	Palbociclib	treatment	2	active_not_recruiting
NCT03698994	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Ulixertinib	treatment	2	active_not_recruiting
NCT04195555	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	Ivosidenib	treatment	2	active_not_recruiting
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Tazemetostat	treatment	2	active_not_recruiting
NCT03233204	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Olaparib	treatment	2	completed
NCT05287295	A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis	Tovorafenib	treatment	2	not_yet_recruiting